Single-lesion biopsy may be insufficient to choose therapy targeting resistance mutations
Sunday, February 7, 2016 - 11:50
in Health & Medicine
When metastatic tumors driven by drug-targetable genetic mutations become resistant to a targeted therapy drug, the usual practice is to test a single metastatic lesion for new mutations that can guide the selection of next-line therapies. But this strategy may miss additional targetable mutations that arise in different metastases, a new study finds.